KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $342.1 million.

  • NovoCure's Cash & Equivalents rose 8450.83% to $342.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $342.1 million, marking a year-over-year increase of 8450.83%. This contributed to the annual value of $163.8 million for FY2024, which is 3199.64% down from last year.
  • As of Q3 2025, NovoCure's Cash & Equivalents stood at $342.1 million, which was up 8450.83% from $149.6 million recorded in Q2 2025.
  • NovoCure's Cash & Equivalents' 5-year high stood at $689.8 million during Q3 2021, with a 5-year trough of $115.3 million in Q4 2022.
  • Its 5-year average for Cash & Equivalents is $252.9 million, with a median of $190.7 million in 2022.
  • Per our database at Business Quant, NovoCure's Cash & Equivalents soared by 19422.25% in 2021 and then crashed by 7195.03% in 2025.
  • Over the past 5 years, NovoCure's Cash & Equivalents (Quarter) stood at $208.8 million in 2021, then tumbled by 44.77% to $115.3 million in 2022, then skyrocketed by 108.82% to $240.8 million in 2023, then crashed by 32.0% to $163.8 million in 2024, then soared by 108.91% to $342.1 million in 2025.
  • Its Cash & Equivalents was $342.1 million in Q3 2025, compared to $149.6 million in Q2 2025 and $127.3 million in Q1 2025.